iDose TR Beats Cataract Surgery Alone in Phase 4, Cutting IOP by 3.6 mmHg More
GKOS has more than doubled off its 52-week low of $73.16 on elevated volume (3.5× avg).
Summary
Glaukos reported positive Phase 4 data showing iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at 3 months versus 7.4 mmHg for surgery alone — a 3.6 mmHg incremental benefit (p<0.0001). The trial met all secondary responder endpoints with a clean safety profile, no corneal endothelial cell loss or cystoid macular edema. This expands iDose TR's label potential into the large cataract surgery population, a key growth driver. The news follows positive Epioxa extension data and an RO-104 licensing deal this week, reinforcing the pipeline momentum. No specific upcoming catalyst was named.
At the time of this announcement, GKOS was trading at $161.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $73.16 to $191.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.